607373-83-1 Usage
Uses
Used in Pharmaceutical Industry:
2-Chloro-4-methoxy-5-nitropyridine is used as a building block for the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with specific therapeutic properties. It plays a crucial role in the creation of novel compounds with potential applications in treating various diseases and medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-4-methoxy-5-nitropyridine is employed as an intermediate in the production of pesticides and other crop protection agents. Its chemical properties enable the development of effective and targeted agrochemicals that can protect crops from pests and diseases, thereby ensuring food security and agricultural productivity.
Used in Dye and Pigment Industry:
2-Chloro-4-methoxy-5-nitropyridine is utilized as an intermediate in the synthesis of dyes and pigments for various applications, including textiles, plastics, and printing inks. Its presence in these compounds contributes to the color intensity, stability, and performance of the final products.
Used in Organic Compounds Synthesis:
As a versatile chemical intermediate, 2-Chloro-4-methoxy-5-nitropyridine is employed in the synthesis of a wide range of organic compounds. Its unique structure allows for the creation of new molecules with specific properties, which can be used in various industries, such as chemical, materials science, and research.
Safety Precautions:
Due to its hazardous nature, 2-Chloro-4-methoxy-5-nitropyridine should be handled and stored with extreme caution. Proper safety measures, including the use of personal protective equipment, should be taken to minimize the risk of exposure. Additionally, it is essential to follow the recommended guidelines for the disposal and management of hazardous substances to mitigate potential health and environmental risks.
Check Digit Verification of cas no
The CAS Registry Mumber 607373-83-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,0,7,3,7 and 3 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 607373-83:
(8*6)+(7*0)+(6*7)+(5*3)+(4*7)+(3*3)+(2*8)+(1*3)=161
161 % 10 = 1
So 607373-83-1 is a valid CAS Registry Number.
InChI:InChI=1/C6H5ClN2O3/c1-12-5-2-6(7)8-3-4(5)9(10)11/h2-3H,1H3
607373-83-1Relevant articles and documents
METHODS OF MAKING NETUPITANT AND INTERMEDIATES THEREOF
-
Paragraph 0044, (2015/11/25)
Methods are disclosed for the preparation of netupitant and pharmaceutically acceptable salts thereof which are novel, easily reproducible, environmentally safe and cost effective. The methods may employ inexpensive starting materials and the preparation processes for intermediates are simple and highly reproducible. Novel intermediates for the preparation of netupitant and pharmaceutically acceptable salts thereof are also disclosed. Amorphous netupitant and methods of making same are disclosed.
TRIAZOLONE COMPOUNDS AND USES THEREOF
-
Paragraph 00219; 00283, (2013/09/26)
The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.